ligand
(Sulfoisobutyl)
assay
≥90% (HPLC)
form
resin
manufacturer/tradename
Calbiochem®
parameter
8 bar max. pressure, 80 cm/hr flow rate
matrix active group
methacrylate
mean particle size
20-40 um μm
capacity
150 mg binding capacity (lysozyme/ml of resin)
transition temp
flash point 35 °C (Does not sustain combustion.)
density
1.43 g/cm3 at 20 °C
bulk density
1000 kg/m3
separation technique
strong cation exchange
shipped in
ambient
storage temp.
2-8°C
Packaging
- 1.16882.0100: Fractogel® EMD SO3- (S) Resin 100ml
- 1.16882.0010: Fractogel® EMD SO3- (S) Resin 10ml
- 1.16882.0500: Fractogel® EMD SO3- (S) Resin 500ml
- 1.16882.5000: Fractogel® EMD SO3- (S) Resin 5L
Analysis Note
Appearance: Milky turbid suspension, free from impurities (foreign particles)
Microscopic evaluation: Uniform spherical particles,no agglomerates,no fines
Extractable matter (water): ≤ 0.05 %
Cerium: ≤ 10 µg/g
Pressure drop(column: ID=1.6 cm, L=10 cm at 5 ml/min): ≤ 5.0 bar
Particle size (d10): 20 - 28 µm
Particle size (d50): 24 - 34 µm
Particle size (d90): 28 - 38 µm
Colony forming units (TAMC + TYMC): ≤ 100 CFU/ml
Endotoxins: ≤ 1.00 EU/ml
Protein binding capacity (lysozyme): 120 - 180 mg/ml
Functional test (c:d): ≤ 0.15
Functional test (b:a): ≤ 0.15
Functional test: Separation chymotrypsinogen A, cytochrom C and lysozyme
Microscopic evaluation: Uniform spherical particles,no agglomerates,no fines
Extractable matter (water): ≤ 0.05 %
Cerium: ≤ 10 µg/g
Pressure drop(column: ID=1.6 cm, L=10 cm at 5 ml/min): ≤ 5.0 bar
Particle size (d10): 20 - 28 µm
Particle size (d50): 24 - 34 µm
Particle size (d90): 28 - 38 µm
Colony forming units (TAMC + TYMC): ≤ 100 CFU/ml
Endotoxins: ≤ 1.00 EU/ml
Protein binding capacity (lysozyme): 120 - 180 mg/ml
Functional test (c:d): ≤ 0.15
Functional test (b:a): ≤ 0.15
Functional test: Separation chymotrypsinogen A, cytochrom C and lysozyme
Legal Information
CALBIOCHEM is a registered trademark of Merck KGaA, Darmstadt, Germany
FRACTOGEL is a registered trademark of Merck KGaA, Darmstadt, Germany
Disclaimer
Toxicity: Standard Handling (A)
signalword
Warning
hcodes
Hazard Classifications
Flam. Liq. 3
存储类别
3 - Flammable liquids
wgk
WGK 1
flash_point_f
95.0 °F
flash_point_c
35 °C
使用 Emprove® 计划保持符合 GMP 要求
使用Emprove® Dossiers可加快资格认证、保持合规性并节省时间。
下载 Dossiers
注意：您将进入 EmproveSuite.com。您的用户名和密码与 SigmaAldrich.com 是分开的，可能不同。
免费注册，几分钟内即可访问 Emprove® Dossiers。 升级您的订阅计划，解锁 Emprove® Suite 中的高级定制内容。
没有找到您要找的内容？访问 Emprove® 计划帮助页面。
M F Jarvis et al.
The Journal of pharmacology and experimental therapeutics, 295(3), 1156-1164 (2000-11-18)
Adenosine (ADO) is an inhibitory neuromodulator that can increase nociceptive thresholds in response to noxious stimulation. Inhibition of the ADO-metabolizing enzyme adenosine kinase (AK) increases extracellular ADO concentrations at sites of tissue trauma and AK inhibitors may have therapeutic potential
Jean De Vry et al.
European journal of pharmacology, 491(2-3), 137-148 (2004-05-14)
The chronic constriction injury model is a rat model of neuropathic pain based on a unilateral loose ligation of the sciatic nerve. The aim of the present study was to test its sensitivity to various clinically validated and experimental drugs.
E A Kowaluk et al.
The Journal of pharmacology and experimental therapeutics, 295(3), 1165-1174 (2000-11-18)
Adenosine kinase (AK; EC 2.7.1.20) is a key intracellular enzyme regulating intra-and extracellular concentrations of adenosine (ADO), an endogenous neuromodulator, antinociceptive, and anti-inflammatory autocoid. AK inhibition provides a means of potentiating local tissue concentrations of endogenous ADO, and AK inhibitors